As of Oct 9, 2026 close
- Market cap
- $2.07B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $9.28$20.22
- Volume (live)
- -
- Avg. volume (3M)
- 2.19M
Trevi Therapeutics (TRVI) Stock Price & Financial Analysis
Trevi Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.81 - $13.46 |
|---|---|
| 52-Week High | $20.22 |
| 52-Week Low | $9.28 |
| Open | $13.14 |
| Volume (last close) | 4.77M |
| Average Volume (3M) | 2.19M |
| Market Cap | 2.07B |
|---|---|
| Shares Outstanding | 156.60M |
| Price to Book (P/B) | 6.42 |
| EV/EBITDA | -37.44 |
| 50-Day MA | $16.37 |
|---|---|
| 200-Day MA | $14.28 |
| 1-Year Change | +32.03% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Trevi Therapeutics at a Glance
Trevi Therapeutics (TRVI) has a market capitalization of $2.07B.
It holds $54.30M in cash and securities against $605.00K of debt, a net cash position of $53.70M.
Trevi Therapeutics does not currently pay a dividend.
The share price is up 32.0% over the past year. At $13.19 it sits within its 52-week range of $9.28 to $20.22, below its 200-day moving average of $14.28.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $29.00, 119.9% above the latest close.
Frequently Asked Questions About Trevi Therapeutics
What is the current stock price for TRVI?
As of the Oct 12, 2026 close, TRVI stock trades at $12.93. The 52-week range is $9.28–$20.22, with a day range of $12.81–$13.46.
What is the P/E ratio for TRVI?
The P/E ratio (Price-to-Earnings) for TRVI is shown in the Key Statistics section. This valuation metric helps compare Trevi Therapeutics, Inc. to industry peers.
Does TRVI pay dividends?
Trevi Therapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.
What do analysts recommend for TRVI?
Based on 10 analysts, the consensus for TRVI is Buy.
What is the market cap of TRVI?
Trevi Therapeutics's market capitalization is $2.02B, classifying it as a mid-cap company. Trevi Therapeutics operates in the Healthcare sector within the Biotechnology industry.